CT radiomic signature predicts survival and chemotherapy benefit in stage I and II HPV-associated oropharyngeal carcinoma
Year: 2023
Type: article
Study design: Observational Study
Abstract: Chemoradiation is a common therapeutic regimen for human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC). However, not all patients benefit from chemotherapy, especially patients with low-risk characteristics. We aim to develop and validate a prognostic and predictive radiomic image signature (pRiS) to inform survival and chemotherapy benefit using computed tomography (CT) scans from 491 stage I and II HPV-associated OPSCC, which were divided into three cohorts D1–D3. The prognostic performance of pRiS was evaluated on two test sets (D2, n = 162; D3, n = 269) using concordance index. Patients from D2 and D3 who received either radiotherapy alone or chemoradiation were used to validate pRiS as predictive of added benefit of chemotherapy. Seven features were selected to construct pRiS, which was found to be prognostic of overall survival (OS) on univariate analysis in D2 (hazard ratio [HR] = 2.14, 95% confidence interval [CI], 1.1–4.16, p = 0.02) and D3 (HR = 2.74, 95% CI, 1.34–5.62, p = 0.006). Chemotherapy was associated with improved OS for high-pRiS patients in D2 (radiation vs chemoradiation, HR = 4.47, 95% CI, 1.73–11.6, p = 0.002) and D3 (radiation vs chemoradiation, HR = 2.99, 95% CI, 1.04–8.63, p = 0.04). In contrast, chemotherapy did not improve OS for low-pRiS patients, which indicates these patients did not derive additional benefit from chemotherapy and could be considered for treatment de-escalation. The proposed radiomic signature was prognostic of patient survival and informed benefit from chemotherapy for stage I and II HPV-associated OPSCC patients.
Source: npj Precision Oncology
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,490
Funders: U.S. Department of Defense, U.S. Department of Veterans Affairs, Eli Lilly and Company, AstraZeneca, Division of Cancer Prevention, National Cancer Institute, National Institutes of Health, National Cancer Institute, National Center for Research Resources, DOD Prostate Cancer Research Program, DOD Peer Reviewed Cancer Research Program
Awards: RadxTools for assessing tumor treatment response on imaging, SYSTEMS BIOLOGY APPROACH TO PREDICTING AND ASSESSING RESPONSE TO CHEMORADIATION FOR BRAIN TUMORS, G1313646905, G1828163000, G2291306530, BIOMEDICAL ENGINEERING RESEARCH FACILITIES, G2689512122, G2702511943, G2800195642, G3068466812, G3716872827, CHIRP Computerized Histologic Risk Predictor (CHiRP) for Early Stage Lung Cancers, G406353596, G4119534169, Lung cancer in East Africa and the relationship to HIV-1 infection: epidemiology, molecular characterization and imaging, G4626068991, G4860676569, HistoTools: A suite of digital pathology tools for quality control, annotation and dataset identification, MR Fingerprinting and Computerized Decision Support for Prostate Cancer, FUSED BIOMARKER-BASED PREDICTION OF AGGRESSIVE FROM INDOLENT PROSTATE CANCER, Computerized histologic image predictor of cancer outcome, Quantitative Histomorphometric Risk Classifier (QuHbIC) in HPV + Oropharyngeal Carcinoma, G5850682332, NOVEL CT-DERIVED RADIOMIC BIOMARKERS FOR LUNG NODULE CHARACTERIZATION IN THE SCREENING POPULATION, G6123616905, QUANTITATIVE VESSEL TORTUOSITY AS BIOMARKER FOR PREDICTING AND MONITORING RESPONSE TO IMMUNOTHERAPY FOR NON-SMALL CELL LUNG CANCER FROM ROUTINE CT SCANS, G7463916530, G761790451, G7645043935, G7935030457, G8166743225, G854738250, COMPUTATIONAL HISTOMORPHOMETRIC PREDICTOR OF PATHOLOGIC RESPONSE AND DISEASE RECURRENCE FOR TRIPLE-NEGATIVE BREAST CANCER, Novel Radiomics for Predicting Response to Immunotherapy for Lung Cancer, Oral Cavity Quantitative Histomorphometric Risk Classifier (OHbIC) in Oral Cavity Squamous Cell Carcinoma (OC-SCC), G942918344
OpenAlex ID: W4379185125